Ahuja P, et al. (2022) Src homology 3 domain binding kinase 1 protects against hepatic steatosis and insulin resistance through the Nur77-FGF21 pathway. Hepatology 35363898

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S344-p - Nur77 (mouse) ▲

Modsite: KEVVRTDsLKGRRGR SwissProt Entrez-Gene Orthologous residues Nur77 (human): S341‑p, Nur77 iso2 (human): S354‑p, Nur77 (mouse): S344‑p, Nur77 (rat): S340‑p Characterization Methods used to characterize site in vivo:  [32P] ATP in vitro, mutation of modification site, phospho-antibody, western blotting Relevant cell lines - cell types - tissues:  293 (epithelial), Hepa 1-6 (epithelial), liver Cellular systems studied:  cell lines, tissue Species studied:  human, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE SBK (human) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE SBK (human) transfection of inactive enzyme, genetic knockout/knockin of upstream enzyme, siRNA inhibition of enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes palmitate increase high-fat diet increase siRNA decrease SBK1 siRNA Downstream Regulation Effect of modification (process):  signaling pathway regulation, transcription, altered Comments:  regulates the Nur77– FGF21 pathway